Krystal Biotech Announces Second Quarter 2026 Financial and Operating Results
Krystal Biotech reported Q2 2026 revenue of $119.2 million, a 24% increase from the prior year, driven by global demand for VYJUVEK which achieved a 95% gross margin. The company ended the quarter with $1.1 billion in cash and investments and reiterated its plans to launch VYJUVEK in Spain and Italy by the end of the year.
Key figures
- Eps
- 1.79
- Revenue
- 119200000
- Guidance
- FY 2026 Non-GAAP combined R&D and SG&A expense $175.0 - $195.0 million
- Revenue Yoy
- 24%
- Net income
- 54800000
- Gross margin
- 95%
- Cash and investments
- 1100000000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.